INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo ILVICO® TABLETS

SCHEDULING STATUS:
Schedule 2

PROPRIETARY NAME
(and dosage form):

ILVICO® TABLETS

COMPOSITION:
Each tablet contains:
Brompheniramine maleate 3 mg
Calcium ascorbate 36 mg
Isopropyl phenazone 75 mg
Salicylamide 150 mg
Quinine hydrochloride 20 mg
Caffeine 10 mg
PHARMACOLOGICAL CLASSIFICATION:
A.5.8. - Preparations for the common cold, includig nasal decongestants and antihistaminics.

PHARMACOLOGICAL ACTION:
Ilvico is an effective antihistamine preparation which reduces swelling and excess secretions of the mucous membranes. Ilvico has analgesic, anti-inflammatory and antipyretic actions.

INDICATIONS:
Ilvico is a compound preparation for the symptomatic treatment of colds influenza, infections of the upper respiratory tract, nasal catarrh, rhinitis, sinusitis and hay-fever.

CONTRA-INDICATIONS:
Brompheniramine may exhibit some anti-cholinergic action which can vary. Ilvico is therefore contra-indicated in patients with glaucoma or prostatic hypertrophy. Ilvico is contra-indicated in patients with peptic ulcers, severe renal impairment, haemophilia and patients receiving oral anti-coagulant therapy. Quinine HCl may cause pregnant women to abort and Ilvico tablets are therefore contra-indicated in pregnant women. Ilvico tablets are contra-indicated in patients who are hypersensitive to quinine and in patients suffering from a chronic and inadequately controlled malarial infection.

WARNINGS:
Ilvico
may cause drowsiness and sedation. Patients using Ilvico should not control vehicles and machinery where lack of concentration could result in accidents. The simultaneous intake of alcohol or other central nervous system depressant agents may potentiate any sedative effect of Ilvico.

Do not use continuously for more than 10 days without consulting your doctor.

DOSAGE AND DIRECTIONS FOR USE:
Children 8 - 12 years: One tablet four times daily.

Adults and children over 12 years: Two tablets four times daily.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Ilvico
may irritate the gastric mucosa with resultant dyspepsia and haematemesis and melaena may occur in some cases. Ilvico may give rise to symptoms such as nausea vomiting, tinnitus, sweating, headache, abdominal pain, skin rashes, dizziness and drowsiness.
Prolonged and excessive usage of Ilvico may lead to anaemia, blood dyscrasias, gastro-intestinal bleeding, peptic ulceration and renal papillary necrosis.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
The symptoms of overdosage may include dizziness, tinnitus, sweating, nausea, vomiting, mental confusion, respiratory and renal failure. Treat symptomatically and use gastric lavage where indicated. In children serious signs of overdosage may develop rapidly.
In cases of overdosage, consult a doctor immediately.

CONDITIONS OF REGISTRATION:
None.

IDENTIFICATION:
Off-white, shiny, round coated tablet, rounded on both sides. (Highly biconvex).

PRESENTATION:
Carton containing 24 or 100 tablets in blister packaging.

STORAGE INSTRUCTIONS:
Keep out of reach of children.
Store below 25°C

REFERENCE NUMBER:
C.770 (Act 101/1965).

NAME AND BUSINESS ADDRESS OF THE APPLICANT:
Merck (Pty) Ltd
Reg. No 70/04059/07
11 Fedlife Park.
Tonetti Street, Midrand 1685

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
18 February 1982.

® = Registered Trade Mark
F19606
89K0791

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2003